NAVIGATOR: Tezepelumab Could Transform Severe Uncontrolled Asthma Care
AstraZeneca/Amgen's Positive Top-Line Phase III Results
In top-line results from the Phase III NAVIGATOR study, AstraZeneca/Amgen’s human monoclonal antibody tezepelumab has significantly reduced disease exacerbations in patients with severe asthma regardless of their type of inflammation, including those with low eosinophil counts.
You may also be interested in...
Recently-submitted tezepelumab reduced the annualized asthma exacerbation rate by 86% in a subgroup of patients with severe, uncontrolled asthma and nasal polyps, according to data presented at the European Respiratory Society congress.
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.
Ruud Dobber oversees AstraZeneca’s biopharmaceuticals division, which generates some 40% of group total revenues. He tells Scrip to “Watch this space.”